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PCR has been used as an aid in the diagnosis of invasive aspergillosis for almost 2 decades. A lack of
standardization has limited both its acceptance as a diagnostic tool and multicenter clinical evaluations,
preventing its inclusion in disease-defining criteria. In 2006, the European Aspergillus PCR Initiative was
formed. The aim of the initiative was to provide optimal standardized protocols for the widespread clinical
evaluation of the Aspergillus PCR to determine its diagnostic role and allow inclusion in disease diagnosis
criteria. Quality control panels were developed and circulated to centers for evaluation of the existing meth-
odology before recommendations based on the initial results were proposed for further panels. The centers
were anonymously classified as “compliant” or “noncompliant,” according to whether they had followed the
proposed recommendations before the performance parameters were determined and meta-regression analysis
was performed. Most PCR amplification systems provided similar detection thresholds, although positivity was
a function of the fungal burden. When PCR amplification was combined with DNA extraction, 50% of the
centers failed to achieve the same level of detection. Meta-regression analysis showed positive correlations
between sensitivity and extraction protocols incorporating the proposed recommendations and the use of bead
beating, white cell lysis buffer, and an internal control PCR. The use of elution volumes above 100 l showed
a negative correlation with sensitivity. The efficiency of the Aspergillus PCR is limited by the extraction
procedure and not by PCR amplification. For PCR testing of whole blood, it is essential that large blood
volumes (>3 ml) be efficiently lysed before bead beating to disrupt the fungal cell and performance of an
internal control PCR to exclude false negativity. DNA should be eluted in volumes of <100 l.
Despite the improved awareness of, and ability to diagnose,
invasive aspergillosis (IA), definitive diagnosis of IA remains
challenging. Clinical signs may be no more specific than fever
of unknown origin refractory to treatment with broad-spec-
trum antibiotics, and classical mycology is seldom useful. With
more people surviving protracted bouts of immunosuppression
as a result of chemotherapy or preparation for stem cell trans-
plantation, the incidence of disease will continue to rise. Mor-
tality rates are high, approaching 100% for cerebral disease,
but they can be reduced by the early initiation of antifungal
therapy (14, 24). However, without an accurate diagnosis, cli-
nicians frequently resort to empirical antifungal therapy, ex-
posing patients to unnecessary treatment and its associated
toxicity and side effects.
Health care providers also incur extra costs, with the annual
cost of treating fungal infections in Europe running into mil-
lions of euros (26). Moreover, patients diagnosed with IA often
require extended hospital care, leading to supplementary costs
estimated to be 75,000 euros per patient, underlining the med-
ical and socioeconomic importance of IA (26).
The introduction of nonculture techniques has enhanced the
ability to diagnose IA in patients at high risk. In neutropenic
patients, pulmonary abnormalities consistent with IA, such as
nodules often surrounded by a “halo sign,” can be detected by
high-resolution computed tomography (8). However, the halo
sign is transient and is detectable only during early IA, after
which radiological signs become nonspecific or appear too late
to be therapeutically useful (3). Commercially available tests
for the detection of galactomannan antigen and beta-D-glucan
show variable performance characteristics and are influenced
by the prevalence of the disease, the testing strategy used, age,
the underlying condition, concomitant therapy with certain
antimicrobials, and even food consumption (10, 19, 21, 27).
The successful PCR-aided diagnosis of IA has been re-
ported in many publications (29). However, the widespread
acceptance of the PCR diagnosis of IA has been hindered by
a lack of standardization, compounded by limited knowl-
edge of the disease process. A multicenter evaluation is
required to overcome the statistical bias introduced by the
relatively low frequency of IA, which is often 10% or less in
high-risk populations. Paradoxically, it is unlikely that an
appropriate evaluation will be achieved until a standard for
PCR is agreed upon.
In 2006, a publication describing the design and clinical
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evaluation of an Aspergillus PCR technique was accompanied
by an editorial highlighting the fact that even though a PCR for
the detection of Aspergillus in human specimens has existed for
almost 2 decades, the technique was not included in the Eu-
ropean Organization for Research and Treatment of Cancer
and the Mycoses Study Group (EORTC/MSG) consensus def-
initions for the diagnosis of invasive fungal diseases (IFDs)
because of a lack of standardization (1, 4, 5, 31). Later that
year, the United Kingdom Fungal PCR Consensus Group
published an agreed-upon methodology for the PCR-aided
diagnosis of IA within the United Kingdom and Ireland
(30). Those reports galvanized a group of mainly European
experts into forming the European Aspergillus PCR Initia-
tive (EAPCRI) working group of the International Society for
Human and Animal Mycoses (ISHAM), which involved more
than 60 centers across Europe and which included centers in
Australia and the Middle East. EAPCRI agreed to collaborate
to develop a standard for an Aspergillus PCR methodology and
to validate this in clinical trials so that PCR could be incorpo-
rated into future consensus definitions for the diagnosis of
IFDs. EAPCRI consists of laboratory, clinical, and statistical
working groups and a steering committee charged with focus-
ing the overall direction of the group, providing a link between
the working parties, and also raising the necessary funds (www
.eapcri.eu).
Here we report on the process, findings, and methodological
recommendations of the EAPCRI Laboratory Working Party
(LWP) for a PCR used to test blood. The preferred function of
the PCR was as a screening test rather than a confirmatory test.
The aim was to ensure the highest sensitivity to attain the
maximum negative predictive value, as this has been the most
pressing issue in clinical practice, and to obtain an assay suited
to the diagnosis of diseases with relatively low incidence rates.
MATERIALS AND METHODS
As the study described here was primarily an analytical validation of the
Aspergillus PCR, the study followed the guidelines of the Standards for Report-
ing of Diagnostic Accuracy, where applicable (2). A summary of the EAPCRI
laboratory standardization process is shown in Fig. 1.
Participants. LWP comprised a core group of 8 laboratories and an extended
group of an additional 16 laboratories. The centers had both clinical and scien-
tific expertise in the field. All centers were designated by a numerical code, which
allowing unbiased assessment of the results by the core group and the mainte-
nance of impartiality throughout the analytical process.
Specimens. The literature supports the use of EDTA-anticoagulated whole
blood (WB), serum, and bronchoalveolar lavage (BAL) fluid (29). For the initial
laboratory standardization (quality control [QC]), WB was selected as the target
specimen, as it can be obtained by relatively noninvasive means, and large WB
specimen volumes from all adult patients may be used for high-frequency screen-
ing. WB is a clinical sample whose use is more technically demanding and
methodologically diverse than serum, and its use requires greater assay standard-
ization. WB was obtained from healthy volunteers, and the samples were pooled.
Panels. For the QC panels, 3-ml WB aliquots were provided and represented
the midpoint volumes used in studies described in the literature. All WB material
was tested for the presence of contaminating Aspergillus spp. before it was
processed (30, 31). To avoid airborne contamination, the processing of all ma-
terial took place in a category 2 laminar-flow hood. The QC panels were spiked
with Aspergillus fumigatus conidia (strain ATCC 1022) quantified by use of a
Fuchs-Rosenthal counting chamber. Negative controls consisting of fungus-free
blood were included. Two WB panels were distributed in 2007 and 2008, respec-
tively (Fig. 1).
To determine whether DNA extraction or PCR amplification was rate limiting,
an additional DNA panel focusing solely on the performance of PCR amplifi-
cation was also distributed alongside the WB panel distributed in 2007 (Fig. 1).
DNA was extracted from 106 A. fumigatus conidia before it was serially diluted.
The expediency of the panel was tested by an Aspergillus-specific real-time PCR
(30, 31). The acceptable threshold for the PCR performance panel was deter-
mined, and the DNA concentration in the specimen was equivalent to approx-
imately 50 A. fumigatus conidia eluted in 100 l or 27 rRNA gene copies per l
eluate, when the mean number of copies of the rRNA genes is considered to be
54 per A. fumigatus genome (9). The mean cycle threshold (CT) value was 35.3
cycles (upper limit, 38.8 cycles) and corresponded to the typical CT values
obtained by the core group when WB from patients with proven/probable IA was
tested. It was essential that all PCR methods evaluated be able to attain this level
of detection. PCR methods not performing to this standard were considered
suboptimal. Additional dilution factors were included to identify methods with
enhanced PCR performance (EPCR). Negative controls consisting of molecular-
grade water were included.
The QC panels were designed to determine the detection limit and concen-
trated on clinically relevant low fungal burdens, with between 70 and 80% of the
specimens in each WB panel being spiked with less than 100 conidia per speci-
men. To validate the panels, initial blind testing was performed by the core group
(n 8) before distribution of the panels and blind testing by all centers (n 24).
After the panels were developed, the distributing center froze all panels at
80°C for up to 1 week with no freeze-thaw intervals. The panels were circulated
on dry ice for next-day delivery by courier. The receiving centers were asked to
confirm receipt of the panel, comment on the state of the panel (frozen or
thawed), and keep the specimens frozen at 80°C until they were tested. Any
panels that were received thawed would be noted and the results would be
excluded from further analysis. A control panel was kept by the distributing
center and was tested for validity on confirmation of the receipt of the panels
from all receiving centers.
DNA extraction. For the 2007 WB panel, the distribution centers were en-
couraged to use the existing methodology. This typically involved the lysis of
human blood cells prior to enzymatic or mechanical fungal cell lysis and then
DNA purification and precipitation with a commercial kit. Following analysis of
the first distribution panel, extraction recommendations (process the entire 3-ml
specimen and use bead beating for fungal cell lysis) that all centers were en-
couraged to incorporate into their existing methods for testing of the 2008 WB
panel were proposed.
PCR amplification. Because there was no universally standardized PCR
method, the participating centers were told to use their current amplification
systems. For all panels, it was recommended that the DNA extracts be tested in
duplicate and preferably in triplicate. The use of an internal control PCR was a
prerequisite. It was decided that the use of nested PCR assays should be avoided,
as these were considered too prone to producing false-positive results.
Defining compliance. When the specimens in the 2008 WB panel were tested, the
centers were graded as “compliant” or “noncompliant,” depending on whether they
had followed the proposed recommendations: to use the entire specimen provided,
use bead beating to lyse the fungal cells, use an internal control PCR to avoid
false-negative results, and perform PCR analysis at least in duplicate.
Data analysis. The centers were requested to return their results within a
designated time frame and provide detailed protocols for their DNA extraction
and PCR amplification systems. For the 2008 WB panel distribution, for which
methodological recommendations had been proposed, the core group, blinded to
the individual assay performance and center identity, scrutinized the procedures
for compliance. The various protocols used for the 2008 panel are summarized
in Tables 1 and 2. A data analysis subgroup was elected to confirm the classifi-
cations and to determine covariates for blinded statistical analysis by an inde-
pendent party.
Statistical analysis. The data produced by the responding centers were qual-
itative and quantitative. Qualitative data were coded as true positive (positive
PCR result obtained with blood spiked with Aspergillus conidia), false positive
(positive PCR result obtained with blood that did not contain Aspergillus
conidia), true negative (negative PCR result obtained with blood that did not
contain Aspergillus conidia), and false negative (negative PCR result obtained
with blood spiked with Aspergillus conidia). The diagnostic odds ratio (DOR),
sensitivity, and specificity were calculated. For the evaluation of the diagnostic
accuracy indices, the specimen with 10 conidia per 3 ml was excluded due to the
possible influence of burden variability between replicates. The sensitivity, spec-
ificity, and DOR were also transformed to their logits in order to obtain a normal
distribution of values. In order to manage the heterogeneity arising from the
different centers (random effects), the effects exerted by several categorical
(binary) covariates on sensitivity, specificity, and DOR were evaluated by meta-
regression methods. The covariates are shown in Table 3. The random-effects
inverse variance weighting method was used for calculations related to meta-
analytic pooling and meta-regression (25).
Linear regression analysis was performed for the centers providing CT values.
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The relationship between this quantitative outcome and the number of Aspergil-
lus conidia/3 ml was investigated by use of a mixed-effects restricted-maximum-
likelihood regression procedure to take into account the heterogeneity at the
center level.
The efficiency of the PCR was calculated by using the equation 1 
10(1/slope).
RESULTS
The panels were distributed to a total of 24 centers on two
separate occasions (in 2007 and 2008). Of these centers,
83.3%, 91.7%, and 87.5% returned results within the allocated
time frame for the PCR performance panel, the 2007 WB
panel, and the 2008 WB panel, respectively.
Determination of Aspergillus PCR performance. Of the 24
centers receiving the panels, 23 actively tested the PCR per-
formance panel, although 2 centers were unable to return
results due to technical difficulties and an additional center
experienced distribution delays. Eighteen of the 20 centers
achieved the required detection limit of approximately 27
rRNA copies/l eluate and used 11 different PCR protocols
(Table 2). Nine of the 18 centers using seven different PCR
protocols showed EPCR and consistently detected lower fun-
gal burdens equivalent to 5 A. fumigatus conidia at a concen-
tration of 2.7 rRNA copies/l eluate (Table 2). There was no
statistically significant difference between the mean PCR effi-
ciency for the different platforms used. The specificity of the
PCR methods tested was 95.2%.
The impact of DNA extraction on PCR performance. Cen-
ters meeting the required PCR performance threshold should
achieve a similar performance when they test spiked WB, pro-
FIG. 1. Summary of the EAPCRI Aspergillus PCR standardization process.
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vided an efficient DNA extraction method is used. The WB
threshold was 50 conidia loaded into a 3-ml specimen. The use
of any PCR system coupled with an inefficient extraction sys-
tem would fail to achieve these standards.
The 2007 WB panel. Nine of the 22 centers returning results
for the 2007 WB panel achieved the required WB detection
threshold. All nine centers achieved the prerequisite PCR per-
formance threshold using seven different PCR protocols
(PCRs 1, 3, 5, 6, 7, 9, and 13), and six centers had EPCR for the
detection of lower fungal burdens by the use of five PCR
protocols (PCRs 1, 5, 6, 7, and 13). Eight of the nine centers,
including all six centers with EPCR, used the entire WB spec-
imen for extraction, and the other center used 75% of the
blood supplied. Eight of the nine centers, including all six
centers with EPCR, used bead beating to disrupt the fungal
cell. One center used lyticase to remove the fungal wall. Two
additional centers that did not reach the WB extraction thresh-
old also used the entire specimen and lyticase. Six centers that
failed to reach the required WB threshold disrupted the fungal
cell with bead-beating-based methods but did not use the en-
tire specimen. Three centers that failed to reach the WB
threshold did not use a recognized fungal cell lysis step. One
center had major contamination issues (specificity, 0%), rais-
ing doubt as to the significance of the results, and another
center experienced distribution delays. Eight of the 11 centers
that failed to achieve the WB threshold achieved the prereq-
uisite PCR performance threshold and three centers had
EPCR, indicating the importance of the use of an efficient
DNA extraction technique.
These findings formed the basis for the DNA extraction
recommendations for testing of the 2008 WB panel. By con-
ventional meta-analytical pooling, the overall sensitivity for the
first WB panel was 64.5% (95% confidence interval [CI], 49.0
to 77.5%) and the overall specificity was 89.6% (95% CI 79.1
to 95.2%). The DOR was 15.1 (95% CI, 4.4 to 52.2).
The 2008 WB panel. Twelve compliant centers followed the
recommendations when they tested the 2008 panel, whereas
nine centers did not and, consequently, were deemed noncom-
pliant (Table 1). The number of centers achieving the required
WB detection threshold was 14, and those centers used nine
different PCR protocols (Table 1). Twelve of the 14 centers
reaching the WB threshold used the entire specimen, and all
used bead beating to lyse the fungal cell. Eleven of these 14
centers were classified as compliant. Twelve of the 14 centers
(9/11 compliant centers) attaining the WB threshold were also
capable of detecting the lower fungal burdens by using seven
different PCR protocols (PCRs 1, 2, 6, 7, 10, 12, and 13).
However, one compliant center had major contamination
problems (specificity, 11.1%). Of the seven centers that failed
to reach the required threshold, six centers were noncompliant
and one center was compliant.
The overall sensitivity was statistically significantly greater
for the second WB panel and the specificity was not compro-
mised, resulting in an improved DOR. By conventional meta-
analytical pooling, an overall sensitivity of 80.60% (95% CI,
68.20 to 88.94%), a specificity of 86.29% (95% CI, 76.06 to
92.58%), and a DOR of 39.79 (95% CI, 12.44 to 127.33) were
calculated (Table 4). The mean positivity rate was a function of
TABLE 1. Summary of methods used to test the 2008 EAPCRI WB panela
Center Vol (ml)used RCL WCL
Fungal
lysis Method of fungal DNA purification
DNA
strategy
Internal
control PCR
No. of
replicates Compliant
PCR
strategy
2 3 Yes Yes B. beating QIAamp Blood kit (Qiagen) DNA 1 No 3 No PCR 1
3 3 Yes No B. beating MagNA Pure LC Total NA kit (Roche) DNA 2 Yes 3 Yes PCR 2
4 1–2 Yes No Lyticase Phenol-chloroform DNA 3 Yes 1 No PCR 3
5 3 Yes Yes Lyticase DNAeasy Tissue (Qiagen) DNA 4 No 3 No PCR 4
6 3 Yes No B. beating MagNA Pure LC DNA kit I (Roche) DNA 5 No 3 No PCR 5
7 3 Yes No B. beating ZR Fungal/Bacterial DNA kit
(Zymo research)
DNA 6 Yes 3 Yes PCR 6
8 1.5 Yes No B. beating SeptiFast kit (Roche) DNA 7 Yes 3 No PCR 7
9 3 Yes Yes B. beating SeptiFast kit (Roche) DNA 8 Yes 3 Yes PCR 7
10 3 Yes Yes B. beating MagNA Pure LC Total NA kit (Roche) DNA 9 Yes 3 Yes PCR 1
11 3 Yes Yes B. beating Tissue kit, EZ1 (Qiagen) DNA 10 Yes 3 Yes PCR 8
13 3 Yes Yes B. beating High Pure Template PCR kit (Roche) DNA 11 Yes 3 Yes PCR 1
14 3 Yes Yes B. beating SeptiFast kit (Roche) DNA 8 Yes 3 Yes PCR 9
15 3 No No B. beating QIAamp blood kit (Qiagen) DNA 12 Yes 3 Yes PCR 1
16b 3 ND ND B. beating QIAamp DNA minikit (Qiagen) DNA 13 Yes 3 Yes PCR 10
17 3 Yes Yes Lyticase DNA Lego kit (Top Bio) DNA 14 No 3 No PCR 11
18 3 Yes No B. beating MagNA Pure LC DNA kit I (Roche) DNA 5 No 3 No PCR 5
19 3 Yes Yes B. beating GeneXpert (Cepheid) DNA 15 Yes 3 Yes PCR 12
20 3 Yes Yes B. beating High Pure Template PCR kit (Roche) DNA 11 Yes 1 No PCR 2
21 2 Yes No B. beating SeptiFast kit (Roche) DNA 7 Yes 3 No PCR 1
22 3 Yes Yes B. beating High Pure Template PCR kit (Roche) DNA 11 Yes 3 Yes PCR 13
23 3 Yes Yes B. beating bioMérieux MiniMagc DNA 16 Yes 3 Yes PCR 1
a The results for the centers that used methods that attained the detection threshold are indicated in boldface. These included 11 compliant centers and 3
noncompliant centers. Eleven different DNA extraction techniques were used together with nine different PCR protocols by the 14 centers attaining the threshold, 9
of which were compliant; 8 attained the PCR performance threshold, and 5 achieved enhanced PCR performance. No results were received from centers 1 and 12,
whereas logistical limitations prohibited the participation of center 24. Abbreviations: RCL, red cell lysis; WCL, white cell lysis; B. beating, bead beating; ND, not
disclosed.
b The specificity of the assay was poor (11.1%).
c For the extraction reagents, any possible contaminating DNA sources were removed by magnetic silica treatment.
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the conidial concentration, which was the greatest for the
higher fungal burdens, and the rates for the 2008 panel were
better than those for the 2007 panel (Table 5 and Fig. 2). The
sensitivity and DOR showed considerable interlaboratory vari-
ability, resulting in two distinct populations, although most
centers achieved satisfactory specificity (Table 4 and Fig. 3).
Upon further investigation, it was shown that the sensitivity for
compliant centers was significantly greater than that for non-
TABLE 3. Categorical binary covariates investigated
by regression methods
Covariate Explanation
Extraction method .....................Compliant with extraction
recommendations: yes or no
Blood vol useda ..........................Entire blood vol used: yes or no
Beadsa ..........................................Beads for mechanical cell wall
disruption used: yes or no
Internal controla .........................Internal control PCR used: yes or no
RCLB...........................................Red cell lysis buffer used: yes or no
WCLB..........................................White cell lysis buffer used: yes or no
NaOH ..........................................NaOH used as lytic agent: yes or no
Purification..................................A protocol for DNA purification was
used after bead beating
More than nine
manual steps ...........................Number of manual steps exceeds
nine: yes or no
ITS ...............................................Internal transcribed spacer (ITS)
target used for Aspergillus PCR:
yes or no
18S................................................18S rRNA gene target used for
Aspergillus PCR: yes or no
28S................................................28S rRNA gene target used for
Aspergillus PCR: yes or no
Elution vol...................................Elution vol below 100 l: yes or no
Low specificity ............................Less than 100% specificity: yes or no
a Criteria used to determine compliance.
TABLE 2. Details of the PCR systems and performance by testing of the PCR performance panela
Center PCR format Platform Genetarget
Detection threshold
(no. of copies/l)b
PCR
strategy
1 RT hydrolysis (TaqMan) probe Rotorgene 28S gene 27 PCR 1
2 RT hydrolysis (TaqMan) probe LightCycler 28S gene 2.7 PCR 1
3 RT hydrolysis (TaqMan) probe TaqMan 18S gene 0.27 PCR 2
4 Nested PCR Conventional 18S gene 27 PCR 3
5 RT hybridization (FRET) probes LightCycler 18S gene No positive results PCR 4c
6 RT hybridization (FRET) probes LightCycler 18S gene 27 PCR 5c
7 RT hydrolysis (TaqMan) probe Rotorgene ITS2 gene 2.7 PCR 6
8 RT hybridization (FRET) probes LightCycler ITS gene 27 PCR 7
9 RT hybridization (FRET) probes LightCycler ITS gene 2.7 PCR 7
11 RT hydrolysis (TaqMan) probe TaqMan 18S gene 27 PCR 8
12 RT hydrolysis (TaqMan) probe LightCycler 28S gene 27 PCR 1
14 RT hybridization (FRET) probes LightCycler ITS gene 27 PCR 9
15 RT hydrolysis (TaqMan) probe Mx3000P 28S gene 2.7 PCR 1
16 RT FAM molecular beacons LightCycler ITS1 gene 270d PCR 10
17 Nested PCR Conventional 18S gene 2.7 PCR 11
18 RT hybridization (FRET) probes LightCycler 18S gene 2.7 PCR 5c
19 RT hydrolysis (TaqMan) probe Smartcycler 18S gene 27 PCR 12
20 RT hydrolysis (TaqMan) probe TaqMan 18S gene 27 PCR 2
22 RT hybridization (FRET) probe LightCycler ITS gene 2.7 PCR 13
23 RT hydrolysis (TaqMan) probe Rotorgene 28S gene 2.7 PCR 1
24 Nested PCR Conventional 18S gene 270e PCR 3
a A total of 13 different PCR strategies were used by the 21 centers that returned results. Assays with enhanced PCR performance for the detection of conidia below
the threshold of detection are indicated in boldface. PCR 1 is the assay of White et al. (31). Three of five centers that used that assay achieved enhanced PCR
performance. Five of five centers that used that assay attained the threshold. The assay was also one of two assays deemed to be optimal by the United Kingdom Fungal
PCR Consensus Group (30). PCR 2 is the assay of Kami et al. (12). One of two centers that used that assay achieved enhanced PCR performance. Two of two centers
that used that assay attained the threshold. The assay was also one of two assays deemed to be optimal by the United Kingdom Fungal PCR Consensus Group (30).
Note that the assay should not be performed on the Roche LightCycler system (30). PCR 5 is the assay described by Klingspor and Jalal (13) and Loeffler et al. (17).
One of two centers that used that assay achieved enhanced PCR performance. Two of two centers that used that assay attained the threshold. PCR 6 is the assay of
Lengerova et al. (15). The one center that used that assay achieved enhanced PCR performance. PCR 7 is the Roche Septifast test. One of two centers that used that
assay achieved enhanced PCR performance. Two of two centers that used that assay attained the threshold. PCR 13 is the assay of Loeffler et al. (16). The one center
that used that assay achieved enhanced PCR performance. As PCR 11 is a nested PCR system, its use is not recommended by the EAPCRI. Centers 10, 13, and 21
were unable to return results. Abbreviations: RT, real-time; FRET, fluorescence resonance energy transfer; FAM, 6-carboxyfluorescein; Rotorgene, Corbett Rotorgene
apparatus; LightCycler, Roche LightCycler apparatus, various models; TaqMan, Applied Biosystems TaqMan apparatus, various models; Mx 3000P, Stratagene
Mx3000P apparatus; Smartcycler, Cepheid Smartcycler apparatus.
b As determined by the PCR performance panel.
c The PCR 4 and PCR 5 assays use the same probes but use slightly different primer sequences.
d PCR 10 was able to reproducibly detect 0.27 copies/l but failed to detect 2.7 and 27 copies/l.
e The panel was delayed in transit and results excluded from analysis.
TABLE 4. Mean performance statistics for protocols used in the
2008 EAPCRI WB panela
Extraction
protocol
Sensitivity Specificity DOR
% 95% CI % 95% CI Value 95% CI
All 80.6 68.2–88.9 86.3 76.1–92.6 39.8 12.4–127.3
Compliant 88.7 79.8–94.0 91.6 79.1–96.9 119.9 44.9–319.9
Noncompliant 57.6 37.9–75.2 77.2 61.2–87.9 8.9 1.7–45.5
a Twelve centers that used 10 different DNA extraction protocols and 9 dif-
ferent PCR amplification procedures were compliant. Nine centers that used
seven different DNA extraction protocols and seven different PCR amplification
procedures were noncompliant. The differences between the compliant and the
noncompliant centers were statistically significant for sensitivity (P  0.008) and
DOR (P  0.006).
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compliant centers (Table 4 and Fig. 3). Six centers failed to
achieve 100% specificity, and five of these centers had been
classified as noncompliant. To exclude the possibility that pos-
itive results arose from contamination and the calculation of
false associations, a further meta-analysis was performed with-
out the results from those six centers.
There was a positive correlation by bivariate meta-regres-
sion analysis between sensitivity and the compliant protocols,
the use of bead beating, and the use of an internal control PCR
(Table 6). Multivariate regression analysis determined positive
correlations between sensitivity and the use of white cell lysis
buffer (t 2.95, P 0.018), bead beating (t 2.57, P 0.033),
and an internal control PCR (t  2.25, P  0.054) but a
negative correlation between sensitivity and the use of elution
volumes greater than 100 l (t  2.53, P  0.035).
DISCUSSION
The results from this study showed that most PCR amplifi-
cations systems assessed (18/20, 90%) efficiently detected the
equivalent of 50 A. fumigatus conidia and that 45% (9/20) were
able to detect the equivalent of 5 A. fumigatus conidia (Table
TABLE 5. Positivity rates for the two EAPCRI WB panels and PCR performance panela
Fungal load
(total no. of conidia)
Potential total no. of
rRNA copiesb No. of copies/l
c
Positivity rate (% no. of PCR tests)
PCR panel (n  52) 2007 panel (n  61) 2008 panel (n  59)
2.7  105 94.2 (49) NT NT
2.7  104 94.2 (49) NT NT
	10,000 5.4  105 5.4  103 NT 77.0 (47) NT
2.7  103 92.3 (48) NT NT
1,000 5.4  104 5.4  102 NT 75.4 (46) 98.3 (58)
500 2.7  104 2.7  102 94.2 (49) 57.4 (35) 98.3 (58)
100 5.4  103 5.4  101 NT 34.4 (21) 78.0 (46)
75 4.1  103 4.1  101 NT 36.1 (22) 67.8 (40)
50 2.7 103 2.7  101 86.5 (45) 37.7 (23) 74.6 (44)
20–25 1.1–1.4  103 1.1–1.4  101 NT 29.5 (18) 62.7 (37)
10 5.4  102 5.4 NT 27.9(17) 49.2 (29)
2.7 40.4 (21) NT NT
0d 0 0 2.9 (3)e 4.9 (6)f 11.3 (20)g
a A total of 22 centers contributed results for the PCR performance panel and the 2007 WB panel, although 1 center returned results only for the PCR panel, while
another returned results only for the WB panel. For the 2008 WB panel, 21 centers returned the results. The theoretical threshold is indicated in boldface. NT, not
tested in this panel.
b Based on 54 copies of rRNA copies per genome (9).
c The calculations were based on 100% extraction efficiency and an elution volume of 100 l.
d The 1st panel contained two negative control specimens. The 2nd panel contained three negative control specimens.
e As the panel contained two negative specimens, the total number of tests was 104 and not 52.
f For one center, both negative specimens were PCR positive. As the panel contained two negative specimens, the total number of tests was 122 and not 61.
g As the panel contained three negative specimens, the total number of tests was 177 and not 59.
FIG. 2. The probability of a positive Aspergillus PCR signal when the 2008 WB panel is tested. The vertical dashed reference lines indicate
(log-transformed) conidial loads of 10, 25, 50, 75, 100, 500, and 1,000. They intersect the various platform-specific logistic curves at the indicated
probability levels. Twenty-one centers performed 59 tests on each specimen. Ten centers used the Roche LightCycler apparatus to perform a total
of 30 replicates for each specimen, five centers used the Applied Biosystems TaqMan apparatus to perform a total of 13 replicates, two centers
used the Corbett Rotorgene apparatus to perform a total of 6 replicates, and four centers used other platforms to perform a total of 10 replicates.
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2). However, half the centers suffered dramatic reductions in
detection thresholds when they tested the 2007 WB panel,
highlighting the impact of the WB DNA extraction procedures
used. Indeed, the extraction procedure appears to be the rate-
limiting step and focused the investigations accordingly. De-
tailed assessment of the extraction methods used with the 2007
WB panel showed that protocols that used the entire specimen
and bead beating were associated with better performance and
were recommended for use for analysis of the 2008 WB panel,
resulting in improved positivity rates (Table 5). It is accepted
that the spiking of blood with conidia does not accurately
reflect disease, as angioinvasion occurs via hyphal penetration.
However, it is not possible to accurately quantify hyphae that
may also be multinucleate, resulting in interspecimen varia-
tions. The recommended beat-beating protocol is equally ef-
fective at disrupting hyphae (28).
Three noncompliant centers (centers 2, 8, and 21) achieved
excellent analytical sensitivity, and evaluation of their proto-
cols revealed one center (center 2) that had been deemed to be
noncompliant for not using an internal control PCR but oth-
erwise had followed the recommendations (Table 1). The
other two centers used only half of the specimen provided but
otherwise followed the recommendations. However, two of the
three noncompliant centers (centers 2 and 21) with excellent
sensitivities also generated false-positive results, casting doubt
over the relevance of the putatively true-positive results from
that center. From a diagnostic perspective, any positive results
in which the negative control also tests positive should be
disregarded.
The sensitivities of the compliant systems were	30% higher
than those of the noncompliant systems (Table 4). Only one
compliant center (center 15) generated poor sensitivities. De-
tailed examination of the protocol used by that center showed
that even though the center used the entire specimen, bead
beating, and an internal control PCR, it made no attempt to
remove the human blood cells (Table 1). This would have
reduced the sensitivity, as white cell lysis is positively associ-
ated with sensitivity. Only one compliant center (center 16)
had poor specificity, and this was reflected in a reduced diag-
nostic odds ratio (Fig. 3).
A high degree of analytical sensitivity is essential, as the
fungal burden circulating in the bloodstream is low (17, 20).
The use of larger sample volumes allows the detection of lower
concentrations of fungal burden because both the overall
amount of target and the opportunity for retrieval are in-
creased (23). Paradoxically, too much extrinsic DNA may in-
hibit the PCR process, so it is essential that an internal control
be used to prevent the reporting of false-negative results.
Statistical analysis between sensitivity and the other covari-
ates showed that the recommendations (use of the entire spec-
TABLE 6. Bivariate meta-regression analysis between logit
sensitivity and the additional covariates for centers
with 100% specificitya
Covariate t P
Compliant extraction method 2.69 0.018
Blood vol used 0.22 0.829
RCLB 1.12 0.285
WCLB 2.08 0.058
NaOH 1.59 0.137
Beads 2.59 0.023
Purification 1.14 0.274
More than nine manual steps 0.46 0.650
ITS 1.54 0.148
18S 1.89 0.082
28S 0.48 0.637
Internal control PCR 2.85 0.015
Elution vol 0.75 0.469
a n  15 centers. t, slope/standard error of the slope. A positive t value
indicates a favorable correlation and vice versa. Significant correlations are
indicated by a P value of 0.05 and are indicated in boldface.
FIG. 3. Forest plot of sensitivity (a) and DOR (b) for each center
participating in testing of the 2008 EAPCRI WB panel. Individual
centers are indicated by numbers. The centers are grouped according
to their compliance with the extraction protocol. The effect size sen-
sitivity (%) and DOR. The closed rhomboids indicate the average
values of sensitivity/DOR at the group level.
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imen, bead beating, and an internal control PCR) and the
individual stage of white cell lysis were all positively associated
with sensitivity. Conversely, negative correlations were associ-
ated with larger elution volumes (	100 l), which reduced the
final DNA concentration.
There were no significant correlations between sensitivity
and the PCR target. However, multicopy targets should be
employed to enhance performance with some strains of A.
fumigatus possessing almost 102 copies of the 18S rRNA gene
(9). All rRNA gene targets (the 18S, 5.8S, 28S, and ITS re-
gions) have the same copy number within individual organisms
but may share significant similarity between fungal species and
the homologous human genes, and both false positivity and
false negativity may be a result of inappropriate oligonucleo-
tide design (30, 32).
Recommendations of EAPCRI. The recommended protocol
for extracting fungal DNA from EDTA-anticoagulated whole-
blood specimens was determined by comparing the protocols
described in Table 1, their associated analytical performance
characteristics, and the statistical association between the in-
dividual steps of the extraction process and sensitivity. The
protocol is illustrated in Fig. 4.
We recommend that EDTA be the only anticoagulant used
for blood specimens, as heparin and sodium citrate have been
associated with inhibition and contamination, respectively (7,
33). Relatively large blood volumes (3 ml) are required, and
FIG. 4. Recommended protocol for extracting Aspergillus DNA from whole blood. Boldface text is expert opinion. The threshold is the
proportion of centers reaching the threshold when the step is used. ppt, precipitation; a, the lysis buffer described previously (6); b, involves 5 min
of processing time and 10 min of incubation time; when frozen specimens are processed, incubation is not necessary.
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it is important to efficiently lyse both red and white blood cells
prior to bead beating to disrupt the fungal cell. Fungal lysis
through recombinant lyticase digestion should be replaced by
bead beating, which removes considerable expense and addi-
tional processing time (30 to 60 min). After the fungal cell is
lysed, commercial protocols can be used to purify, capture, and
elute the DNA. Then different DNA extraction protocols
shown in Table 1 were associated with good analytical sensi-
tivity and specificity. Reagent contamination can be problem-
atic when fungal PCR is performed (18, 22). It is good practice
to screen both commercial and in-house reagents for contam-
ination by using negative extraction controls. Likewise, positive
extraction controls with consistent loads and representative of
typical IA should routinely be used to monitor the perfor-
mance of the extraction procedure. The use of DNA elution
volumes greater than 100 l should be avoided.
Most PCR amplification systems work efficiently, the vari-
ability in current performance appears to be a direct conse-
quence of the extraction technique used, and it is not necessary
to define an individual PCR assay. However, the six real-time
PCR protocols (PCRs 1, 2, 5, 6, 7, and 13) described in Table
2 had EPCR and may provide improved performance when
their use is coupled with the DNA extraction technique de-
scribed in Fig. 4. In general, all PCR testing should be per-
formed at least in duplicate, with further testing being per-
formed as required to interpret contradictory results that may
arise as result of the low fungal burden or the limits of real-
time PCR detection (20). An internal control system should
also be used to avoid false-negative results. The internal con-
trol target should be present at levels similar to those that
result in positive results by a typical Aspergillus PCR (CT val-
ues, 35 to 40 cycles).
These results confirm the analytical validity of the Aspergillus
PCR for the screening and detection of Aspergillus. Further
external validity and the testing accuracy of the proposed
method will be strategically determined by other laboratories
that have expressed an interest in this EAPCRI (11). Studies
into dynamic linearity may also be necessary to determine the
performance of the PCR across various fungal burdens, which
is particularly important in monitoring therapeutic responses.
Studies with animal models are being conducted to compare
the performance of the PCR by using the different specimen
options. Clinical validity also needs to be established in large-
scale prospective trials designed to determine the performance
and utility of the Aspergillus PCR with specimens from high-
risk populations.
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